RadNet Inc
RadNet Inc operates in the healthcare sector, specifically within the Pharmaceuticals & Medical Research business sector, generating revenue through its classified activity in Pharmaceuticals.
Business. RadNet Inc (RDNT.O) is a healthcare company operating within the pharmaceuticals and medical research sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceutical activities.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
RadNet Inc (RDNT.O) is a healthcare company operating within the pharmaceuticals and medical research sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceutical activities.
(a) RadNet Inc maintains a capital structure characterized by significant leverage, with long-term debt of $1.06 billion against total equity of $1.09 billion, resulting in a debt-to-equity ratio of 0.98. The company holds $767.2 million in cash and equivalents, but the risk assessment flags that net cash is negative after subtracting total debt, indicating a medium liquidity risk profile. Total assets stand at $3.76 billion, while total liabilities are $2.40 billion.
(b) Profitability metrics indicate operational challenges, with a return on equity of -1.3% and a return on assets of -0.38%. The company reported a net income loss of $18.7 million despite generating an operating income of $62.0 million, suggesting significant non-operating expenses or interest costs impacting the bottom line. Operating cash flow remains positive at $298.8 million, providing a buffer against the net income deficit.
- RadNet generates $2.04 billion in revenue but reports a net loss of $18.7 million, driven by high leverage and interest expenses.
- The company holds $767.2 million in cash but carries $1.06 billion in long-term debt, resulting in a negative net cash position.
- Analyst sentiment is overwhelmingly positive, with a mean recommendation of 1.62 and a mean price target of $89.75.
- Return on equity is negative at -1.3%, reflecting the impact of debt and net losses on shareholder value.
- Operating cash flow is robust at $298.8 million, providing liquidity support despite the net income deficit.
Bull / Bear case
Generated · model-assistedRevenue grew 11.5% year-over-year to $2.04 billion in fiscal 2026, demonstrating consistent top-line expansion.
Gross profit increased to $430.6 million in fiscal 2026, indicating improved cost of goods sold management.
The company maintained a current ratio of 1.76, suggesting adequate short-term liquidity to meet obligations.
Dilution risk is assessed as low, providing relative stability for existing shareholders regarding equity value erosion.
Free cash flow turned deeply negative at -$44.0 million, reflecting significant cash burn and operational inefficiency.
Long-term debt rose to $1.09 billion, increasing financial leverage and interest burden on the balance sheet.
Credit risk is flagged as high, indicating potential difficulties in meeting debt obligations or securing financing.
In focus — financials by report
Revenue $575.6M, +22,1% YoY; Operating income +0,8% YoY.
- ▍Revenue $575.6M, +22,1% YoY
- ▍Operating income +0,8% YoY
- ▍Net income +11,8% YoY
- ▍Free cash flow −15,3% YoY
- ▍Net margin -5.8%
Revenue $547.7M, +14,8% YoY; Operating income +25,7% YoY.
- ▍Revenue $547.7M, +14,8% YoY
- ▍Operating income +25,7% YoY
- ▍Net income −111,2% YoY
- ▍Free cash flow −104,3% YoY
- ▍Net margin -0.1%
Revenue $522.9M, +13,4% YoY; Operating income −15,9% YoY.
- ▍Revenue $522.9M, +13,4% YoY
- ▍Operating income −15,9% YoY
- ▍Net income +68,8% YoY
- ▍Free cash flow −209,6% YoY
- ▍Net margin 1.0%
Revenue $498.2M, +8,4% YoY; Operating income +18,4% YoY.
- ▍Revenue $498.2M, +8,4% YoY
- ▍Operating income +18,4% YoY
- ▍Net income +584,7% YoY
- ▍Free cash flow +215,5% YoY
- ▍Net margin 2.9%
Revenue $471.4M; Operating income -$24.1M.
- ▍Revenue $471.4M
- ▍Operating income -$24.1M
- ▍Net margin -8.0%
Revenue $477.1M; Operating income $22.1M.
- ▍Revenue $477.1M
- ▍Operating income $22.1M
- ▍Net margin 1.1%
Revenue $461.1M; Operating income $32.6M.
- ▍Revenue $461.1M
- ▍Operating income $32.6M
- ▍Net margin 0.7%
Revenue $459.7M; Operating income $26.1M.
- ▍Revenue $459.7M
- ▍Operating income $26.1M
- ▍Net margin -0.6%
Revenue $2.04B, +11,5% YoY; Operating income −32,7% YoY.
- ▍Revenue $2.04B, +11,5% YoY
- ▍Operating income −32,7% YoY
- ▍Net income −767,8% YoY
- ▍Free cash flow −286,1% YoY
- ▍Net margin -0.9%
Revenue $1.83B, +13,2% YoY; Operating income −6,7% YoY.
- ▍Revenue $1.83B, +13,2% YoY
- ▍Operating income −6,7% YoY
- ▍Net income −8,2% YoY
- ▍Free cash flow +36,2% YoY
- ▍Net margin 0.2%
Revenue $1.62B, +13,1% YoY; Operating income +116,3% YoY.
- ▍Revenue $1.62B, +13,1% YoY
- ▍Operating income +116,3% YoY
- ▍Net income −71,4% YoY
- ▍Free cash flow −159,5% YoY
- ▍Net margin 0.2%
Revenue $1.43B, +8,7% YoY; Operating income −40,4% YoY.
- ▍Revenue $1.43B, +8,7% YoY
- ▍Operating income −40,4% YoY
- ▍Net income −56,9% YoY
- ▍Free cash flow +410,1% YoY
- ▍Net margin 0.7%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,51 |
| Revenue | —no estimate | —no estimate | 2,5B USD |
| Operating income | —no estimate | —no estimate | 123,8M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, President, CEO · Stock Option (right to buy) → Common StockDisposed 25 992 @ $18,64exercise · 2026-05-05
- Director, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 2 493exercise · 2026-03-10
- Director, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 3 742exercise · 2026-03-10
- Director, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 4 987exercise · 2026-03-10
- Director, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 6 237exercise · 2026-03-10
- Director, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 7 481exercise · 2026-03-10
- Director, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 8 727exercise · 2026-03-10
- Director, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 12 466exercise · 2026-03-10
- Director, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 16 831exercise · 2026-03-10
- EVP and Chief Legal Officer · Employee Stock Option (right to buy) → Common StockDisposed 3 396 @ $29,44exercise · 2025-12-10
- EVP, Chief Financial Officer · Employee Stock Option (right to buy) → Common StockDisposed 35 703 @ $6,07exercise · 2025-12-10
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Assetsnet_income / total_assets
- Return On Equitynet_income / total_equity
- RadNet, Inc. Market data — financials · 2026-07-10
- RadNet Inc Market data — analyst estimates · 2026-07-10
- RadNet Inc Market data — ESG · 2026-07-10
- RadNet Inc HA canonical relationships · 2026-07-10
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,03 %$62M
- Investment Managers · as of 2026-03-310,03 %$0M
- Investment Managers · as of 2026-03-310,03 %$50M
- Investment Managers · as of 2026-03-310,02 %$77M
- Funds · as of 2026-03-310,01 %$91M
- Investment Managers · as of 2026-03-310,01 %$20M
- Investment Managers · as of 2024-06-300,01 %$566M
- Investment Managers · as of 2024-12-310,01 %$45M
- Institutional Investor · as of 2026-03-310,01 %$50M
- Investment Managers · as of 2026-03-310,01 %$67M
- Investment Managers · as of 2025-12-310,01 %$532M
- Brokerage Firms · as of 2026-03-310,01 %$24M
- Investment Managers · as of 2026-03-310,01 %$43M
- Investment Managers · as of 2026-03-310,01 %$26M
- Investment Managers · as of 2026-03-310,01 %$96M
- Investment Managers · as of 2026-03-310,01 %$42M
- Investment Managers · as of 2026-03-310,01 %$148M
- Investment Managers · as of 2026-03-310,00 %$27M
- Institutional Investor · as of 2026-03-310,00 %$23M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2026-03-310,00 %$48M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$12M
- Brokerage Firms · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- David ScultPresident & CEO
Insider activity
- Director · Common StockSold 2 699 @ $53,89$145K · 2026-06-18
- Pres & CEO, Digital Health · Common StockSold 4 750 @ $58,11$276K · 2026-06-16
- Director, President, CEO · Common StockOther 90 · 2026-06-16
- Pres & CEO-Eastern Operations · Common StockSold 24 214 @ $57,79$1,4M · 2026-06-15
- Pres & CEO-Eastern Operations · Common StockSold 19 853 @ $58,61$1,2M · 2026-06-15
- Director · Common StockOther 2 946 · 2026-06-02
- Director · Common StockOther 2 946 · 2026-06-02
- Director · Common StockOther 2 946 · 2026-06-02
- Director · Common StockOther 2 946 · 2026-06-02
- Director, President, CEO · Common StockOther 25 992 @ $18,64$484K · 2026-05-05
- Director, Chief Strategy Officer · Common StockSold 9 554 @ $61,84$591K · 2026-03-19
- Director, Chief Strategy Officer · Common StockSold 5 346 @ $62,82$336K · 2026-03-19
- Director, Chief Strategy Officer · Common StockSold 100 @ $63,59$6K · 2026-03-19
- Director, Chief Strategy Officer · Common StockOther 7 000 · 2026-03-19
- Director, Chief Strategy Officer · Common StockSold 14 200 @ $62,12$882K · 2026-03-18
- Director, Chief Strategy Officer · Common StockSold 800 @ $62,72$50K · 2026-03-18
- Director, Chief Strategy Officer · Common StockOther 5 919 @ $61,72$365K · 2026-03-16
- Director, Chief Strategy Officer · Common StockOther 6 237 · 2026-03-10
- Director, Chief Strategy Officer · Common StockOther 3 742 · 2026-03-10
- Director, Chief Strategy Officer · Common StockOther 4 987 · 2026-03-10
- Director, Chief Strategy Officer · Common StockOther 7 481 · 2026-03-10
- Director, Chief Strategy Officer · Common StockOther 8 727 · 2026-03-10
- Director, Chief Strategy Officer · Common StockOther 12 466 · 2026-03-10
- Director, Chief Strategy Officer · Common StockOther 2 493 · 2026-03-10
- Director, Chief Strategy Officer · Common StockOther 16 831 · 2026-03-10
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Revenue (annual): USD 2.04BUnknown
- Operating income (annual): USD 61.99MUnknown
- Cash & equivalents (annual): USD 767.22MUnknown
- Net income (annual): USD -18.65MUnknown
- EPS (basic) (annual): USD-PER-SHARES -0Unknown
- Shareholders' equity (annual): USD 1.09BUnknown
- Total liabilities (annual): USD 2.4BUnknown
- Pre-tax income (annual): USD 31.91MUnknown
- Long-term debt (annual): USD 1.09BUnknown
- Shares outstanding (annual): 77.4MUnknown
- Total operating expenses (annual): USD 1.98BUnknown
- Current assets (annual): USD 1.03BUnknown
- EPS (diluted) (annual): USD-PER-SHARES -0Unknown
- Operating cash flow (annual): USD 298.82MUnknown
- Current liabilities (annual): USD 586.76MUnknown
- Total assets (annual): USD 3.76BUnknown
- Total assets (annual): USD 3.29BUnknown
- EPS (basic) (annual): USD-PER-SHARES 0Unknown
- Shares outstanding (annual): 74.04MUnknown
- Current assets (annual): USD 1.02BUnknown
- Long-term debt (annual): USD 1.02BUnknown
- Operating income (annual): USD 104.62MUnknown
- EPS (diluted) (annual): USD-PER-SHARES 0Unknown
- Shareholders' equity (annual): USD 902.31MUnknown